Savran Technologies
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
90 Bridge St, Newton, Massachusetts, 024...Phone Number
(774) 245-5344Website
www.savrantech.comRevenue
<$5 MillionIndustry
About Savran Technologies
SavranTech specializes in developing next-generation non-invasive diagnostics for critical conditions in women's health, focusing on the early detection of preeclampsia through a simple urine test. Their patented ultra-rare cell detection platform allows for reliable screening as early as 10 weeks of gestation, addressing a significant gap in current diagnostic methods. The company aims to improve maternal and neonatal outcomes by enabling timely interventions and raising the standard of care in maternal health. SavranTech's innovative solutions target healthcare providers and expectant mothers, contributing to better health outcomes for millions of women worldwide.Explore more
Savran Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Savran Technologies
Compare insights from companies similar to Savran Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Savran Technologies Tech Stack
A closer look at the technologies used by Savran Technologies
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Savran Technologies
Sign Up For FreeTo access detailed company insights
SavranTech specializes in developing next-generation non-invasive diagnostics for critical conditions in women's health, focusing on the early detection of preeclampsia through a simple urine test. Their patented ultra-rare cell detection platform allows for reliable screening as early as 10 weeks of gestation, addressing a significant gap in curre... Read More
